TD Cowen analyst Marc Frahm has maintained their bullish stance on SANA stock, giving a Buy rating on October 30.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Marc Frahm has given his Buy rating due to a combination of factors that highlight Sana Biotechnology’s strategic focus and financial positioning. The company has decided to prioritize its SC451 program, which is seen as a high-potential project, and has suspended its allogeneic CAR T development to conserve resources. This strategic shift is expected to extend the company’s cash runway into the second half of 2026, providing stability and focus on its most promising initiatives.
Additionally, Sana’s management has shown confidence in the progress of the SC451 program, having gained clarity from the FDA on the requirements for its GMP master cell bank, a critical step towards an IND filing anticipated in 2026. The company is also advancing its preclinical in vivo CAR program, SG293, with potential IND filing as early as 2027. These developments, along with a reported cash position of $170 million, reinforce the company’s ability to navigate its strategic priorities effectively, justifying the Buy rating.
In another report released on October 30, Citizens JMP also maintained a Buy rating on the stock with a $8.00 price target.